Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.51 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.45 |
| ▸ | PYGL | P06737 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21583789 | 1.00 | SLC6A3 (0.51) | SLC6A3TAS1R3TAS1R1TAS1R2MMP13 | |
| SCHEMBL21583783 | 1.00 | SLC6A3 (0.51) | SLC6A3TAS1R3TAS1R1TAS1R2MMP13 | |
| SCHEMBL21583749 | 0.86 | PYGL (0.55) | TAS1R3TAS1R1TAS1R2METAP2PYGL | |
| SCHEMBL23201911 | 0.86 | PYGL (0.55) | TAS1R3TAS1R1TAS1R2METAP2PYGL | |
| SCHEMBL23201905 | 0.86 | PYGL (0.55) | TAS1R3TAS1R1TAS1R2METAP2PYGL | |
| SCHEMBL23221931 | 0.78 | METAP2 (0.46) | TAS1R3TAS1R1TAS1R2MMP13METAP2 | |
| SCHEMBL27409724 | 0.77 | ALDH1A1 (0.61) | TAS1R3TAS1R1TAS1R2ALDH1A1SMN1; SMN2 | |
| SCHEMBL23221756 | 0.77 | PSMB5 (0.68) | PSMB5 | |
| SCHEMBL23641107 | 0.77 | PSMB5 (0.68) | PSMB5 | |
| SCHEMBL23221930 | 0.77 | PSMB5 (0.68) | PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3805237-B1 | SYNTHESIS AND USES OF PEPTIDE BORATE ESTER COMPOUND | JIANGSU CHUANGTE PHARMACEUTICAL TECH CO LTD (CN) | 2026-01-28 | — | — | EP | disclosed |
| US-11542283-B2 | Synthesis of peptide borate ester compound and use thereof | JIANGSU CHIA TAI FENGHAI PHARMACEUTICAL CO., LTD. (CN) | 2023-01-03 | — | — | US | disclosed |
| US-11542283-B2 | Synthesis of peptide borate ester compound and use thereof | JIANGSU CHIA TAI FENGHAI PHARMACEUTICAL CO., LTD. (CN) | 2023-01-03 | — | — | US | disclosed |
| US-20210214377-A1 | SYNTHESIS OF PEPTIDE BORATE ESTER COMPOUND AND USE THEREOF | JIANGSU CHIA TAI FENGHAI PHARMACEUTICAL CO., LTD. (CN) | 2021-07-15 | — | — | US | disclosed |
| US-20210214377-A1 | SYNTHESIS OF PEPTIDE BORATE ESTER COMPOUND AND USE THEREOF | JIANGSU CHIA TAI FENGHAI PHARMACEUTICAL CO., LTD. (CN) | 2021-07-15 | — | — | US | disclosed |
| EP-3805237-A1 | SYNTHESIS AND USES OF PEPTIDE BORATE ESTER COMPOUND | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CN) | 2021-04-14 | — | — | EP | disclosed |
| EP-3805237-A1 | SYNTHESIS AND USES OF PEPTIDE BORATE ESTER COMPOUND | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CN) | 2021-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214377-A1 | SYNTHESIS OF PEPTIDE BORATE ESTER COMPOUND AND USE THEREOF | SEM1, VIP, PSMB11 | SLC6A3 3322/4885TAS1R3 4434/4885TAS1R1 4310/4885 |
| US-11542283-B2 | Synthesis of peptide borate ester compound and use thereof | SEM1, VIP, PSMB11 | SLC6A3 3322/4885TAS1R3 4434/4885TAS1R1 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.